Evidence regarding SGLT-2 inhibitors for the management of diabetic dyslipidemia

Affiliations

¹ Knight Cardiovascular Institute & Division of Endocrinology Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA. Electronic address: duellb@ohsu.edu.
² Founder and Chair, Lipid Association of India. Sr. Consultant Cardiologist, Indraprastha Apollo Hospitals, New Delhi, India.
³ Department of Cardiology, G.B. Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.
⁴ Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, Irvine, CA, USA.

Comment

P Barton Duell et al. J Clin Lipidol. 2023 May-Jun.

. 2023 May-Jun;17(3):422-423.

doi: 10.1016/j.jacl.2023.04.006. Epub 2023 Apr 28.

¹ Knight Cardiovascular Institute & Division of Endocrinology Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA. Electronic address: duellb@ohsu.edu.
² Founder and Chair, Lipid Association of India. Sr. Consultant Cardiologist, Indraprastha Apollo Hospitals, New Delhi, India.
³ Department of Cardiology, G.B. Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.
⁴ Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, Irvine, CA, USA.

No abstract available

Comment on

Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia.
Seetharaman R, Joshi SS. Seetharaman R, et al. J Clin Lipidol. 2023 May-Jun;17(3):420-421. doi: 10.1016/j.jacl.2023.04.003. Epub 2023 Apr 26. J Clin Lipidol. 2023. PMID: 37137801 No abstract available.